# Chimigen Bio

Source: https://onco.cc/companies/chimigen-bio/  
OnCo record `chimigen-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chimigen Bio makes off-the-shelf treatment vaccines that deliver pieces of a tumour protein straight to the immune cells that start an immune response. Its prostate cancer vaccine, KMV002, began an early trial in 2026 for advanced prostate cancer that no longer responds to hormone treatment.

## Summary

Chimigen Biomedical (Chengdu) Co., Ltd. (凯米生物), in Tianfu International Bio-Town, Chengdu, China, was founded in June 2021, according to the company, and runs a US subsidiary, ChimiVac, in New York, which sponsors its US trial. Its SynNeogen platform uses an Fc fusion design to deliver multi-epitope payloads directly to dendritic cells to activate CD4 and CD8 T cells, which the company calls immune priming therapy. The lead cancer product KMV002 (IPT-PAP), a vaccine against prostatic acid phosphatase for metastatic castration-resistant prostate cancer, received FDA IND clearance in July 2026, entered an early-phase clinical trial in September 2026 and received FDA Fast Track designation in October 2026, according to the company. A second product, SN2001, is in a phase 1 study in Australia for chronic hepatitis B, and the pipeline lists HBV-positive liver cancer and undisclosed programmes in triple-negative breast and digestive cancers. Its first-ever registry study, NCT07059403, posted in July 2025, is not a cancer study as far as the registry data read show; its first registered cancer trial, NCT07866300 (KMV002), was posted on ClinicalTrials.gov in October 2026. The company states it has closed about USD 40 million in financing, including a Pre-Series A round of more than RMB 100 million listed among its 2025 milestones.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Chimigen Biomedical (Chengdu) Co., Ltd.; 凯米生物; ChimiVac; Chimivac Inc
- HQ: Chengdu
- Type: biotech
- Website: https://www.chimigen.com/

## Notes

- The registry sponsor Chimivac INC is matched to Chimigen through the registry contact domain chimigen.com and the company's statement that ChimiVac is its US subsidiary.
- NCT07059403, the sponsor's first registry study, was not in the cached registry data and was not read; it is assumed to be the SN2001 hepatitis B study, which is unconfirmed.
- Milestone dates come from the company's milestone timeline, read in English at chimivac.com and in Chinese at chimigen.com; the year of the Pre-Series A round is taken from its position in that timeline, so no funding row is recorded.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.chimigen.com/
- English website (ChimiVac): http://www.chimivac.com/
- Science and pipeline (Chinese): https://www.chimigen.com/science.html
- ClinicalTrials.gov: phase 1 trial of KMV002 in metastatic castration-resistant prostate cancer (NCT07866300): https://clinicaltrials.gov/study/NCT07866300

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [Prostatic acid phosphatase (ACP3, PAP)](https://onco.cc/targets/pap/)

---
JSON: https://onco.cc/api/v1/entities/chimigen-bio.json